Samsung Biologics aims to raise 2.25t won in IPO
Seoul
SAMSUNG Biologics Co is seeking to raise as much as 2.25 trillion won (S$2.77 billion) from a South Korean initial public offering, taking an important step towards its goal of becoming the world's largest contract manufacturer of biological medicines.
The drug-making arm of the South Korean conglomerate will offer about 16.5 million shares at 113,000- 136,000 won apiece, according to a filing on Tuesday. Samsung Biologics will gauge demand for the share sale from Oct 26 to 27 wi…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Prada’s sales up 16% in first quarter as Miu Miu shines
Toymaker Hasbro posts quarterly profit beat, slower sales decline
Hilton lifts 2024 profit forecast on international travel demand
China knockoff raid jolts a global throng of fake-fashion influencers
Roche cuts pipeline after research setbacks and sales drop
Cordlife customers push for legal action